Buscar resultados de ensayos clínicos
Prader-Willi Syndrome - 30 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome Condición:
Fecha: 2012-01-18 |
Completed |
Nombre del estudio: Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome Condición:
Fecha: 2011-07-31 |
Completed |
Nombre del estudio: Hypoglycemia in Prader-Willi Syndrome Condición:
Fecha: 2013-07-08 Intervenciones: Other: Infants with Prader-Willi Syndrome Participants will be admitted to the outpatient clinical resea |
Completed |
Nombre del estudio: Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome Condición:
Fecha: 2003-08-01 Intervenciones: Drug: Topiramate |
Terminated |
Nombre del estudio: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Condición:
Fecha: 2014-06-25 Intervenciones:
|
COMPLETED |
Nombre del estudio: Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome Condición: Prader-Willi Syndrome Fecha: 2024-05-19 Intervenciones: All patients will consume NBT-NM108 in the form of 2 muffins daily. |
RECRUITING |
Nombre del estudio: Impact of Bright Light Therapy on Prader-Willi Syndrome Condición: Prader-Willi Syndrome Fecha: 2024-05-19 Intervenciones: Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm. |
RECRUITING |
Nombre del estudio: Cerebellar TMS and Satiety in Prader-Willi Syndrome Condición: Prader-Willi Syndrome Fecha: 2024-05-19 Intervenciones: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner.During rTMS a rapidly |
RECRUITING |
Nombre del estudio: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) Condición: Prader-Willi Syndrome Fecha: 2024-05-19 Intervenciones: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks. |
RECRUITING |
Nombre del estudio: Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Condición: Prader-Willi Syndrome Fecha: 2024-05-19 Intervenciones: Initial dose for all participants will be 1mg per day.If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and incre |